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ABSTRACT
Crucial elements for achieving optimal long-
term outcomes in multiple sclerosis (MS) are
patient confidence and effective physician–pa-
tient communication. Patient-reported instru-
ments may provide the means to fill the gap in
currently available clinician-rated measures.
The SymptoMScreen (SMSS) is a brief self-
assessment tool for measuring symptom sever-
ity in 12 neurologic domains commonly affec-
ted by MS. We conducted a non-interventional
study to assess the dimensional structure and
item characteristics of the SMSS. A total of 218
patients with relapsing–remitting MS and mild
disability (median Expanded Disability Status
Scale score 2.0) were studied. Symptom severity
was low (SMSS score 13.5, interquartile range
4.2–27), fatigue being the domain with the
highest impact. A non-parametric item response
theory, i.e., Mokken analysis, found that the
SMSS is a robust one-dimensional scale (overall
scalability index H 0.60) with high reliability
(Cronbach’s alpha 0.94). The confirmatory
factor analysis model confirmed the unidimen-
sional structure (comparative fit index 1.0, root-
mean-square error of approximation 0.001).
Samejima’s model fitted well an unconstrained
model with different item difficulties. The SMSS
shows appropriate psychometric characteristics
and may constitute a valuable and easy-to-
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implement addition to measure the symptom
severity in clinical practice.
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Key Summary Points
Patients’ perspectives may differ from
healthcare professionals’ priorities
Understanding the impact of multiple
sclerosis (MS) symptoms from the
patients’ perspective may facilitate shared
decision-making
The SymptoMScreen is a self-rated
questionnaire to assess symptom severity
in different key neurologic domains
commonly affected by MS. In addition to
its good psychometric properties, it is a
rapid and reliable tool to administer in
clinical practice
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflamma-
tory demyelinating disease of the central ner-
vous system that affects different functional
systems and is associated with progressive dis-
ability [1]. The last 10 years has witnessed a
dramatic increase in the diversity of available
therapies for the management of MS. In this
context, patients, who are commonly less
informed than heathcare professionals on such
aspects as treatment efficacy and the profiles of
side effects, have a limited number of tools
available on which to base their decision-mak-
ing regarding therapy [2–4].
The assessment of patient perspectives can
provide invaluable clinical information that
may otherwise be lost when clinical evaluation
is the primary source of information [3, 4].
Patient-reported outcomes are designed to cap-
ture patient perceptions of their health condi-
tion, functional level, and quality of life.
However, they have been inconsistently
employed in the assessment of patients with MS
[5, 6].
The SymptoMScreen questionnaire (SMSS) is
a self-assessment tool for measuring symptom
severity in 12 critical neurologic domains com-
monly affected by MS: mobility, hand function/
dexterity, spasticity and stiffness, pain, sensory
symptoms, bladder control, fatigue, vision,
dizziness, cognition, depression, and anxiety
[7]. In the few studies on the SMSS conducted to
date, the SMSS total score was found to correlate
with clinical disability, patient-perceived phys-
ical and psychological impact, and work pro-
ductivity (as assessed by the Expanded
Disability Status Scale [EDSS], 29-item Multiple
Sclerosis Impact Scale, and Working Productiv-
ity and Impairment Questionnaire, respec-
tively) [7–9]. The SMSS may encourage patients
to communicate symptom severity in multiple
overt and less tangible key standardized
domains. In addition, this instrument can help
clinicians focus the discussion of symptom
management during the visit, track severity,
and serve as basis for making specific referrals
[7]. The SMSS takes less than 5 min to complete
and may constitute a useful tool to quantify
symptoms in clinical practice [7]. However, the
whole spectrum of its psychometric properties
has not yet been studied and reported.
The aim of this study was to assess the
dimensional structure and item characteristics
of the SMSS in the management of MS.
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METHODS
A non-interventional, cross-sectional study was
conducted in 17 MS units throughout Spain
(PERCEPTIONS-MS Study). Key eligibility crite-
ria included an age of at least 18 years, a diag-
nosis of relapsing–remitting MS according to
the 2010 revised McDonald criteria [10], and an
EDSS score of 0–5.0 [11]. Written informed
consent was obtained from all subjects. The
study was approved by the institutional review
board of the Hospital Universitari Clı´nic (Bar-
celona, Spain) and conformed with the Helsinki
Declaration of 1964, as revised in 2013, con-
cerning human and animal rights, as well as
with Springer’s policy concerning informed
consent.
The SMSS consists of 12 items which are
assessed on a seven-point Likert scale that ran-
ges from 0 (not at all affected) to 6 (total limi-
tation) [7]. The total score ranges from 0 to 72,
with higher scores indicating more severe
symptom endorsement.
Statistical Analysis
The distribution of the SMSS scores was evalu-
ated across different levels of MS severity,
including disease duration, total number of
relapses, EDSS score, and number of disease-
modifying therapies. The early-stage MS defini-
tion was used to establish the disease duration
cutoff (B 3 years from first documented clinical
attack) [8]. We evaluated mean differences and
linear trends using one-way analysis of variance
and linear regression.
A non-parametric item response theory (IRT)
procedure, the Mokken scale analysis, and a
confirmatory factor analysis (CFA) were per-
formed to assess the underlying dimensions of
the SMSS. Each of the 12 items was required to
have a scalability coefficient (Hi) of C 0.30 and
an overall scale scalability index (H) of C 0.30
[12, 13]. A parametric Samejima’s Grade
Response Model (GRM) was also conducted to
further assess the information and discrimina-
tion of SMSS items [14]. We considered a com-
parative fit index (CFI) value[ 0.95 as an
acceptable model fit and root-mean-square error
of approximation (RMSEA) values of\0.08
and\ 0.05 as adequate and good model fit,
respectively. We performed all analyses with R
version 3.6.0 (https://cran.r-project.org/bin/
windows/base/old/3.6.0/) using the libraries
mokken, lavaan, and ltm.
RESULTS
A total of 218 patients were enrolled in the
study and included in the analysis (mean age
39.1 ± 9.5 years, 70.6% female). Symptom
severity was low, and fatigue was the domain
with the highest score (Table 1).
The SMSS scores showed a significant linear
trend relationship with EDSS severity (p value
\0.001), with means ranging from 7.5 (lower
EDSS category) to 28.9 (EDSS value 4), and total
number of relapses (B 2 vs. C 3; p = 0.02). No
significant relationships were found between
SMSS scores and disease duration (B 3
vs.[ 4 years; p = 0.07) and between SMSS scores
and number of MS treatments (1, 2, C 3;
p = 0.08), but the average SMSS scores (± stan-
dard deviation) did show a clear linear trend for
disease duration (12.8 ± 11.2 and 16.6 ± 14,
respectively) and for total number of treatments
(13 ± 13.8, 15.6 ± 12.8, and 18.4 ± 13.3,
respectively).
Internal Reliability The SMSS showed high
reliability (Cronbach’s alpha 0.94, bootstrap
95% confidence interval 0.93–0.95).
Table 1 Clinical characteristics of patients enrolled in the
study
Clinical characteristics Values (N = 218
patients)
Time since diagnosis (years);
mean (SD)
6.6 (4.5)
EDSS score; median (IQR) 2.0 (1.0, 4.0)
SMSS score; median (IQR) 13.5 (4.2, 27.0)
EDSS Expanded Disability Status Scale, IQR interquartile
range, SD standard deviation, SMSS SymptoMScreen
(questionnaire)
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Non-Parametric (Mokken) Item Response The-
ory The SMSS is a robust unidimensional scale
with an overall scalability index of H = 0.60,
and all items showing scalability coefficients of
Hi[ 0.50 (Table 2).
Item Characteristics: Grade Response Model
The item characteristic curves from Samejima’s
GRM showed adequate probability patterns for
response categories with an item-ranking order
for discrimination that also agreed with the
observed order for item information (Table 2).
Factor Structure The CFA model confirmed the
unidimensional structure suggested by Mokken
analysis (RMSEA 0.001, CFI 1.0) (Table 2). All
item coefficients are intrinsically linked regard-
less of the different techniques (non-parametric
IRT, CFA, parametric IRT) as would be expected
when a unidimensional domain underlies all of
them (Fig. 1).
DISCUSSION
Fatigue, pain, heat intolerance, mobility prob-
lems, visual impairment, anxiety, depression,
and cognitive impairment are commonly found
to be associated with work difficulties and poor
productivity in MS patients [15]. MS is a com-
plex disease that cannot be reduced to walking
capacity, and patients must be assessed in many
different aspects in each clinical examination
[3, 5, 6]. In addition, the perspectives and
preferences of a patient may and often do differ
from the priorities of healthcare professionals.
Heesen et al. found that vision, cognition, and
mobility were the most important bodily func-
tions from a patient perspective in a sample of
171 subjects with relapsing–remitting MS [16].
In the present study, visual impairment was not
considered to be relevant by physicians—in
contrast to patients’ opinion. The results of
another quality of life assessment in MS
involving 380 MS patients and 135 neurologists
found a disagreement related to factors
impacting health-related quality of life, with
physicians focusing on physical aspects while
patients considered vitality, pain, and mental
health also to be relevant [17]. The manage-
ment of such disruptive MS-related problems
should be part of patient-centered care [3].
Clinician-rated EDSS is still the most com-
mon instrument used to assess the effectiveness
Table 2 Psychometric characteristics of the patients as assessed according to the 12 items on the SMSS
SMSS items Hi Discrimination
a Informationa CFA standardized coefficients
1 0.572 2.039 5.89 0.722
2 0.618 2.459 8.17 0.783
3 0.623 2.685 8.34 0.793
4 0.644 3.041 11.25 0.833
5 0.629 2.504 8.65 0.784
6 0.593 2.444 6.28 0.757
7 0.634 2.458 8.84 0.803
8 0.579 2.155 6.87 0.724
9 0.585 2.039 6.40 0.738
10 0.658 2.828 11.53 0.821
11 0.528 1.716 5.32 0.647
12 0.557 1.902 5.82 0.696
CFA Confirmatory factor analysis, Hi Scalability coefficient
a Discrimination and information coefficients were from Samejima’s Grade Response Model [14]
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of clinical interventions and to monitor disease
progression despite the several shortcomings of
this assessment tool [18], including inadequate
assessment of several critical domains, such as
cognitive performance, quality of life, and
energy level [18, 19]. In this context, patient-
reported outcome instruments may provide the
means to fill the current gap in patient-centered
impairment measures.
Our study found that the SMSS is a robust
unidimensional scale that shows good psycho-
metric properties regarding internal consistency
and item discrimination and information. The
SMSS shows appropriate convergent validity
with the EDSS and total number of relapses as
well as a linear trend with other surrogate
indicators of severity.
Green et al. [7] developed the SMSS to help
patients to identify and communicate symptom
severity in multiple functional domains rele-
vant for MS. Using this scale, patients rate
symptoms that lead to symptom-related limi-
tations, as opposed to measures of disability like
the EDSS [7, 8]. In a sample of 1865 patients
with MS, the pain, ambulation, and fatigue
domains of the SMSS significantly predicted
patients’ perception of health [20].
This study has a major limitation. The study
population included a sample of clinically
stable relapsing–remitting MS patients with low
physical disability. The results may thus not be
generalizable to less stable subjects and other
clinical subtypes (secondary or primary pro-
gressive forms). Despite this limitation, the
sample of 218 subjects was managed in 17 dif-
ferent MS units on a national level, representing
relapsing–remitting patients across the country.
Fig. 1 Confirmatory factor analysis (CFA) model. Lower
diagonal displays the correlation graphs, upper diagonal
presents Pearson’s correlation estimates, main diagonal
displays the distribution of parameter estimates.
Discrimination and information coefficients are from
Samejima’s Grade Response Model (GRM), Hi Scalability
coefficient
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CONCLUSION
Understanding the impact of symptoms from
the patients’ perspective may facilitate shared
decision-making in MS care. The Symp-
toMScreen is a quick, comprehensive, and reli-
able instrument to assess the severity of
symptoms in clinical practice.
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